GPLB
Green Planet Bioengineering Co., Ltd.0.0125
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
250.08KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Green Planet Bioengineering, a shell company, posted Q3 administrative expenses of $8,599, up from $5,425 y/y, driving net loss wider versus prior year while YTD loss narrowed to $19,544 from $22,753. No revenue, cash, or operations; funding came entirely from related party advances covering $19,514 in operating cash use. Liabilities hit $484,678, matching stockholders' deficit, with $479,148 due to related party (interest-free, on demand). Losses match across operating and net lines. Related party advanced $5,530 post-quarter. Shell status raises funding risks.
10-Q
Q2 FY2025 results
Green Planet Bioengineering, a shell company seeking merger targets, trimmed Q2 administrative expenses to $4,105 from $10,863 y/y, narrowing its operating loss while holding zero cash and revenue. Six-month net loss eased to $10,945 from $17,328 y/y (derived), funded entirely by $12,945 advanced from a related party—up from $18,328 prior year. Related-party debt climbed to $472,579 at quarter-end June 30, 2025, matching the stockholders' deficit. No revenue, no operations. Cash stays zero. Going concern hinges on related-party support.
10-Q
Q1 FY2025 results
Green Planet Bioengineering, a shell company, posted a $6,840 net loss for Q1 ended March 31, 2025, up 5.7% y/y from $6,465 (derived), all from administrative expenses like accounting and filing fees. No revenue, zero cash, yet stockholders' deficit widened modestly to $471,974 on related-party funding of $6,915 covering $6,915 operating cash burn. EPS stayed below $0.01 on 20,006,402 diluted shares, consistent both periods. Related party advanced another $5,425 post-quarter. Funding hinges on majority stockholder support. Going concern doubts loom large.
8-K
Auditor resigns, new one engaged
Green Planet Bioengineering's auditor Assurance Dimensions resigned May 15, 2025, citing its exit from public company audits; prior reports on 2023-2024 financials were clean, with no disagreements or reportable events. The company had engaged Stephano Slack as replacement on March 15, 2025, also without prior consultations or issues. Smooth transition. No audit hiccups disclosed.
10-K
FY2024 results
Green Planet Bioengineering, a public shell seeking merger targets, posted FY2024 net loss of $35,544 on $35,544 administrative expenses, down 25% from $47,670 in 2023, with no revenues or operations. Expenses narrowed steadily, reflecting lighter compliance costs. No Q4 breakdowns disclosed. Related party funded all $35,044 operating cash burn, hiking payable to $459,634. No dividends, buybacks, or capex. Auditors flag going concern doubt sans funding. No guidance issued. Penny stock rules crimp liquidity.
ACBM
ACRO BIOMEDICAL CO LTD
0.00+0.00
FVN
Future Vision II Acquisition Co
10.54+0.00
GIPL
GLOBAL INNOVATIVE PLATFORMS INC
0.11+0.00
GLLI
Globalink Investment Inc.
3.00-8.50
GRAF
Graf Global Corp.
10.71-0.14
GSPI
Green Star Products, Inc.
0.00+0.00
GTERA
Globa Terra Acquisition Corpora
10.08-0.01
LPBB
Launch Two Acquisition Corp.
10.46-0.01
PLPL
Plandai Biotechnology, Inc.
0.00+0.00
TGLO
theglobe.com, inc.
0.49+0.01